CC
SGMO

Centiva Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Centiva Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-308,500
Closed -$111K – 2553
2024
Q2 		$111K Buy
+308,500
New +$167K ﹤0.01% 1831
2023
Q3 		– Sell
-30,539
Closed -$39.7K – 2050
2023
Q2 		$39.7K Buy
+30,539
New +$41.7K ﹤0.01% 1515

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Centiva Capital's SGMO Position: Q3 2024 in Review

Centiva Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2024, closing a stake of 308,500 shares — an estimated $111K sold.

Centiva Capital first reported a position in SGMO in Q2 2023 and held it in 2 quarters. The position peaked at $111K in Q2 2024. 103 funds tracked by Wall St. Rank hold SGMO as of Q3 2024.

  • Centiva Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
  • Centiva Capital sold 308,500 SANGAMO THERAPEUTICS INC shares in Q3 2024, an estimated $111K.
  • Centiva Capital first reported a position in SANGAMO THERAPEUTICS INC in Q2 2023 and held it in 2 quarters.
  • Centiva Capital's SANGAMO THERAPEUTICS INC position peaked at $111K in Q2 2024.
  • 103 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.